On April 1st 2023, the new 5 year contract for Immune Globulin (IG) between Canadian Blood Services and manufacturers went into effect. With this new contract, some changes will be taking place across Canada in regards to certain immune globulin products. We know that some of you have voiced your concern about how these changes will affect you and your care.
IVIG
IVIG patients currently on Gamunex, IVIGnex and Privigen will most likely not see any change in their product. Patients currently on Panzyga, should note that this product will no longer be available with a complete phase-out planned for 2024. Patients currently on Panzyga will be transitioned onto another IVIG. Please discuss with your prescribing physician.
Subcutaneous (SubQ)
Patients currently on Cuvitru or Hizentra should not see any changes in their products.
Cutaquig
Patients currently on Cutaquig should note that this product will no longer be available beginning in late 2023 into early 2024. If you are receiving Cutaquig because you were unable to tolerate or suffered a reaction to another product, you may be eligible for a medical exemption.
Please contact your prescribing physician and/or ImmUnity Canada at info@immunitycanada.org to learn more about the medical exemption process.
We will continue to update you throughout this process, and work with Canadian Blood Services and industry, for the patient, ensuring that patient care is the primary concern to all involved. Please know that ImmUnity Canada is working with CBS, blood banks and specialist treaters across Canada to ensure that inconvenience is minimal and access to product is not disrupted.
Updates will continue to be posted on our website, as well as in our newsletters.
Canadian Blood Services will continue to post updates on their website.